Rightslink® by Copyright Clearance Center

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Author:

Yelena Y Janjigian,Akihito Kawazoe,Yuxian Bai,Jianming Xu,Sara Lonardi,Jean Phillipe Metges,Patricio Yanez,Lucjan S Wyrwicz,Lin Shen,Yuriy Ostapenko,Mehmet Bilici,Hyun Cheol Chung,Kohei Shitara,Shu-Kui Qin,Eric Van Cutsem,Josep Tabernero,Kan Li et al.

Publication:

The Lancet

Publisher:

Elsevier

Date:

9–15 December 2023

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Welcome to RightsLink

Elsevier has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing this content.

I would like to...This drop down menu contains the options the publisher has agreed to permit for reuse of their copyrighted material. The publisher offers these types of use either directly through RightsLink or after approval by the publisher. Please reference the terms and conditions offered during the order process for a complete understanding of the use you select. Need more info?